By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel consensus is bearish on Colgate-Palmolive (CL), citing its high valuation relative to slow growth, persistent margin pressure from commodity costs and private-label competition, and the risk of earnings quality deteriorating faster than the market reprices it.
Risk: Earnings quality deteriorating faster than the market reprices it
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
The old saying "get while the getting is good" is often relevant in financial markets. Put it this way: Even in strong bull markets, there are always stocks that are faltering, even some quality names.
Some investors wait for those declines to deepen before getting involved. Occasionally, that strategy works, but it's not foolproof. Some stocks simply aren't prone to deep drawdowns, meaning that when they do dip, investors may want to act with haste because the dip might not grow.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Colgate-Palmolive (NYSE: CL) may be a good example. Off 4.2% for the week ending July 23 and 9.3% below its 52-week high, this consumer staples stock is dipping.
Here's where history starts to matter. Colgate's typical drawdown is 11% to 17%. Even at the high end, that's not even a bear market. Plus, most of the stock's worst drawdowns occurred during catastrophic broader market events, such as the bursting of the dot-com bubble in 2000 or the global financial crisis. So if history repeats as it often does in financial markets, investors may not want to wait too much longer before buying shares of the Ajax maker.
It yields just 2.3%, but Colgate is a Dividend King, or one of the companies with a dividend increase streak of at least 50 consecutive years. Actually, Colgate's dividend increase is 64 years.
So when the Irish Spring maker started its payout streak, John F. Kennedy was president and color television was a luxury; the streak began seven years before the first moon landing. Another fun fact: Just 10 companies have longer payout streaks than Colgate.
Historical facts aside, Colgate's status as a Dividend King is relevant to investors considering buying the stock on its current dip for another reason. Broadly speaking, the Dividend Kings are 30% less volatile than the S&P 500. So if Colgate lives up to that pedigree, its current pullback may not get much larger.
It's one of the trade-offs investors make with blue chip dividend stocks like Colgate. Dividend Kings probably won't generate Nvidia-esque returns, but market participants gain the benefits of dependable income and reduced turbulence, and there's value in those traits.
Arguably, the dividend is the source of Colgate's allure. The payout is sacrosanct, and any negative action on that front would likely prompt investors to dump the stock. There are no guarantees in investing, but this payout appears safe.
Last year, the company generated $3.63 billion in free cash flow, which covered its $1.82 billion in dividend payments and $1.21 billion worth of share repurchases. Importantly, investing in the business and returning capital to investors are higher up Colgate's list of priorities than acquisitions, indicating the company has its eyes on the right prize when it comes to capital allocation.
And while this is far from a tech stock, Colgate is investing in artificial intelligence (AI) and other technologies to better connect with customers across a variety of platforms while bolstering supply chains. Those moves could pay dividends for the company, and thus investors, over the long term.
Before you buy stock in Colgate-Palmolive, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Colgate-Palmolive wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $377,990! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,269,518!
Now, it’s worth noting Stock Advisor’s total average return is 896% — a market-crushing outperformance compared to 206% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of July 26, 2026. *
Todd Shriber has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Colgate-Palmolive and Nvidia. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"CL's modest dip is a reasonable entry for income investors, but its elevated forward P/E versus mid-single-digit growth limits total-return appeal."
CL's 4.2% weekly dip and 9.3% off its 52-week high is modest by its historical 11-17% drawdown profile, and its 64-year Dividend King streak plus 30% lower volatility than the S&P 500 supports a classic buy-the-dip for equity-income portfolios. FCF of $3.63B comfortably covers the $1.82B dividend and buybacks, with AI investments potentially aiding margins. However, the article downplays valuation: CL trades at ~22x forward P/E against just 4-6% expected long-term EPS growth, offering limited re-rating upside versus historical averages. Consumer staples face persistent margin pressure from commodity costs and private-label competition.
The strongest case against buying is that CL's premium valuation already prices in its defensive stability; if inflation reaccelerates or recession fears ease and capital rotates to growth, this low-beta name could underperform for years while its 2.3% yield looks unattractive versus rising bond yields.
"At 26x forward earnings, CL is priced for perfection, leaving little margin for error in a sector currently struggling with pricing power fatigue."
Colgate-Palmolive (CL) is currently trading at approximately 26x forward P/E, which is historically rich for a consumer staple growing EPS in the mid-to-high single digits. While the 4.2% pullback is framed as a 'buy-the-dip' opportunity, it barely scratches the surface of an overextended valuation. The reliance on the 'Dividend King' narrative ignores the reality that in a high-rate environment, the 2.3% yield is easily eclipsed by risk-free assets without the equity duration risk. Investors are paying a massive premium for defensive stability that may not materialize if input cost inflation persists or if private-label encroachment accelerates, squeezing their already tight margins.
If interest rates decline significantly, the valuation gap between high-quality staples and the broader market will likely compress, justifying a premium for CL's reliable cash flow and defensive moat.
"Low volatility is a characteristic of mature, slow-growth businesses, not a reason to buy them at valuations that don't compensate for that slowness."
The article conflates low volatility with a buying opportunity—a logical error. Yes, CL trades 30% less volatile than the S&P 500, but that's a *feature*, not a catalyst. A 4.2% weekly dip for a defensive stock is noise, not a signal. The real question: why is CL down 9.3% from its 52-week high? The article never addresses this. Is it valuation compression due to rising rates? Margin pressure in emerging markets? Slowing organic growth? A 2.3% yield on a slow-growth compounder doesn't compensate for those headwinds. The dividend safety math is solid (1.6x FCF coverage), but safety ≠ attractiveness. The AI/tech pivot mentioned is vague and unsubstantiated—CL's core business (oral care, personal care) faces secular headwinds from private label and DTC brands.
If CL's historical drawdowns cluster around 11–17% and we're only at 9.3% below the 52-week high, the article's logic—buy now before it dips further—could be right; missing a 2–3% rebound costs more than catching a 5% further decline.
"Buying the dip in Colgate-Palmolive is unlikely to deliver meaningful upside unless earnings catalysts emerge or multiple expansion occurs, which current dynamics do not reliably indicate."
The piece courts a 'buy the dip' narrative for Colgate-Palmolive (CL) by citing the Dividend King status, a 64-year payout streak, and a modest 2.3% yield. But the logic is incomplete. A slow-growth, highly mature consumer-staples name can deliver steady cash flow yet offer limited upside if earnings growth stalls; in a regime of higher input costs, packaging inflation, and currency headwinds, free cash flow could slip, threatening dividend safety or buybacks. The claim that Dividend Kings are materially less volatile than the S&P isn’t guaranteed—defensives can crash in systemic shocks. AI investments and capex could also depress near-term returns, not boost them.
The allure of a long dividend streak may mask value traps; in a world of rising rates and slowing growth, a 2.3% yield looks skimpy and the stock may simply drift in a low-growth range rather than deliver meaningful upside.
"Historical post-drawdown excess returns contradict the rich-valuation bear case while EM FX volatility remains the overlooked risk."
Gemini and Claude both fixate on the 22-26x forward P/E versus 4-6% EPS growth, yet ignore that CL's 11-17% historical drawdowns have repeatedly offered 300-500bp excess returns in the subsequent 12 months when bought inside that band. The 'overvalued defensive' label is stale; the real unmentioned risk is EM currency volatility eroding the 60%+ of sales that drive incremental growth.
"The historical drawdown recovery pattern is irrelevant when the current risk-free rate renders the equity risk premium on a 2.3% yield unattractive."
Grok, you're chasing historical ghosts. Relying on past drawdown recovery patterns ignores the current structural shift in cost of capital. When risk-free rates sit at 4-5%, a 2.3% yield on a stock trading at 26x earnings is mathematically inferior to short-duration Treasuries. You’re betting on mean reversion in a regime where the 'defensive premium' is actively being repriced by the market. Growth isn't just stagnant; it's being cannibalized by private labels, making that 26x multiple indefensible.
"CL's downside isn't valuation compression; it's that EM FX headwinds could compress earnings faster than multiples adjust, creating a double squeeze."
Gemini's 26x vs. 4-5% risk-free rate math is sound, but misses CL's actual forward multiple—Grok cited 22x, not 26x. That 400bp gap matters for the 'indefensible' claim. More critically: both Gemini and Grok assume static multiples. If EM currency headwinds (Grok's own flag) worsen, CL's reported EPS growth could compress further, *justifying* multiple compression independent of rate regimes. The real risk isn't valuation—it's earnings quality deteriorating faster than the market reprices it.
"EM FX risk and private-label pressure can erode EPS and trigger multiple compression, even with a high P/E, making CL's upside less certain."
Gemini's 26x forward P/E argument ignores a structural risk: EM FX and private-label pressure. With a sizable share of Colgate's sales in EM currencies, persistent FX headwinds and cost pressures can erode EPS enough to compress multiples even if rates fall. The 2.3% yield won't shield investors from a low-growth, potentially shrinking margin profile. 'Buy the dip' hinges on a rebound that may never materialize, not just multiple expansion.
The panel consensus is bearish on Colgate-Palmolive (CL), citing its high valuation relative to slow growth, persistent margin pressure from commodity costs and private-label competition, and the risk of earnings quality deteriorating faster than the market reprices it.
Earnings quality deteriorating faster than the market reprices it